美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NewcelX Ltd.

3.30

-0.0755-2.23%

盤後：3.300.00000.00%19:30 EDT

成交量：3,750

成交額：1.23萬

市值：1,766.32萬

市盈率：-1.53

高：3.32

開：3.30

低：3.22

收：3.38

52周最高：24.60

52周最低：1.83

股本：534.52萬

流通股本：273.89萬

量比：0.79

換手率：0.14%

股息：- -

股息率：- -

每股收益(TTM):-2.1600

每股收益(LYR):-2.1592

淨資產收益率：--

總資產收益率：-25.94%

市淨率：2.44

市盈率(LYR):-1.53

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

NewcelX任命世界知名糖尿病治療先驅Camillo Ricordi博士加入科學顧問委員會

Newcelx宣佈FDA臨床前會議成功，為Ncel-101啓動1型糖尿病臨床試驗鋪平道路

NewcelX公布2025財年業績攜手Eledon製藥加速推進2026年1型糖尿病療法研發進程

Newcelx更新企業演示文稿，重點展示與Eledon製藥戰略合作後的1型糖尿病旗艦項目，瑞士生物技術會議前揭曉

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/NCEL"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NCEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":3.3045,"timestamp":1789156800000,"preClose":3.38,"halted":0,"volume":3750,"hourTrading":{"tag":"盘后","latestPrice":3.3045,"preClose":3.3045,"latestTime":"19:30 EDT","volume":5,"amount":16.5,"timestamp":1789169404893,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.022337278106508845,"floatShares":2738900,"shares":5345200,"eps":-2.159999,"marketStatus":"休市中","change":-0.0755,"latestTime":"09-11 16:00:00 EDT","open":3.3,"high":3.323748,"low":3.2239,"amount":12342.291,"amplitude":0.029541,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.159999,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":3.38,"postHourTrading":{"tag":"盘后","latestPrice":3.3045,"preClose":3.3045,"latestTime":"19:30 EDT","volume":5,"amount":16.5,"timestamp":1789169404893,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7859328482501303},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","floatShares":2738900,"roa":"-25.94%","roe":"--","lyrEps":-2.159218,"volumeRatio":0.7859328482501303,"shares":5345200,"dividePrice":0,"high":3.323748,"amplitude":0.029541,"preClose":3.38,"low":3.2239,"week52Low":1.8299,"pbRate":"2.44","week52High":24.6,"institutionHeld":0,"latestPrice":3.3045,"eps":-2.159999,"divideRate":0,"volume":3750,"delay":0,"ttmEps":-2.159999,"open":3.3,"prevYearClose":1.9,"prevWeekClose":3.35,"prevMonthClose":3.275,"prevQuarterClose":3.66,"fiveDayClose":3.35,"twentyDayClose":3.6,"sixtyDayClose":3.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-04-30","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-10-31","symbol":"NCEL","defaultRemindTime":1761917400000,"type":"split","dateTimestamp":1761883200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-16","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747368000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-09-27","symbol":"NCEL","defaultRemindTime":1727443800000,"type":"split","dateTimestamp":1727409600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCEL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCEL","date":"2026-09-11","current":-1.529862,"percent":0.098592,"low":-2.743828,"twenty":-2.24955,"median":-0.871696,"eighty":-0.593951,"high":-0.434312,"avg":-1.335035,"sd":0.793932,"marketCap":19523312},"quantilePoints":[{"date":"2025-10-31","current":-2.085416,"twenty":-2.085416,"median":-2.085416,"eighty":-2.085416,"marketCap":39937082.48},{"date":"2025-11-07","current":-0.993097,"twenty":-1.495376,"median":-1.229626,"eighty":-1.098389,"marketCap":18917268},{"date":"2025-11-14","current":-0.808829,"twenty":-1.253274,"median":-0.970727,"eighty":-0.876223,"marketCap":15635236},{"date":"2025-11-21","current":-0.750891,"twenty":-1.145695,"median":-0.878334,"eighty":-0.814355,"marketCap":14358890},{"date":"2025-11-28","current":-0.957951,"twenty":-1.045743,"median":-0.867781,"eighty":-0.806793,"marketCap":18279095},{"date":"2025-12-05","current":-0.856292,"twenty":-0.972009,"median":-0.871696,"eighty":-0.812974,"marketCap":16455744},{"date":"2025-12-12","current":-0.781666,"twenty":-0.995845,"median":-0.875612,"eighty":-0.812974,"marketCap":15179398},{"date":"2025-12-19","current":-0.635834,"twenty":-0.972009,"median":-0.85736,"eighty":-0.781019,"marketCap":12353204},{"date":"2025-12-26","current":-0.613233,"twenty":-0.957493,"median":-0.83848,"eighty":-0.693066,"marketCap":11988534},{"date":"2026-01-02","current":-0.442896,"twenty":-0.955117,"median":-0.833152,"eighty":-0.615876,"marketCap":8660918},{"date":"2026-01-09","current":-0.513637,"twenty":-0.941907,"median":-0.808829,"eighty":-0.589968,"marketCap":10074015},{"date":"2026-01-16","current":-0.561129,"twenty":-0.915578,"median":-0.78535,"eighty":-0.566624,"marketCap":11122442},{"date":"2026-01-23","current":-0.610165,"twenty":-0.913462,"median":-0.76547,"eighty":-0.561129,"marketCap":12125285},{"date":"2026-01-30","current":-0.576613,"twenty":-0.882218,"median":-0.6841,"eighty":-0.565731,"marketCap":11623863},{"date":"2026-02-06","current":-0.601541,"twenty":-0.878334,"median":-0.628521,"eighty":-0.570197,"marketCap":12034117},{"date":"2026-02-13","current":-0.627168,"twenty":-0.875612,"median":-0.627168,"eighty":-0.572325,"marketCap":12717874},{"date":"2026-02-20","current":-0.632256,"twenty":-0.869347,"median":-0.627168,"eighty":-0.573006,"marketCap":12581123},{"date":"2026-02-27","current":-0.656951,"twenty":-0.860299,"median":-0.626808,"eighty":-0.575926,"marketCap":13082544},{"date":"2026-03-06","current":-0.638142,"twenty":-0.856719,"median":-0.630594,"eighty":-0.581513,"marketCap":12854625},{"date":"2026-03-13","current":-0.639458,"twenty":-0.843011,"median":-0.628376,"eighty":-0.587749,"marketCap":12717874},{"date":"2026-03-20","current":-0.559522,"twenty":-0.837754,"median":-0.626853,"eighty":-0.587749,"marketCap":11168026},{"date":"2026-03-27","current":-0.565498,"twenty":-0.835865,"median":-0.623182,"eighty":-0.571899,"marketCap":11259193},{"date":"2026-04-02","current":-0.537802,"twenty":-0.83268,"median":-0.620613,"eighty":-0.56375,"marketCap":10712188},{"date":"2026-04-10","current":-0.468376,"twenty":-0.821759,"median":-0.618412,"eighty":-0.555851,"marketCap":9527010},{"date":"2026-04-17","current":-0.546102,"twenty":-0.811592,"median":-0.616697,"eighty":-0.55169,"marketCap":11350361},{"date":"2026-04-24","current":-1.072253,"twenty":-0.811592,"median":-0.617492,"eighty":-0.552903,"marketCap":22381635},{"date":"2026-05-01","current":-0.95322,"twenty":-0.83268,"median":-0.620255,"eighty":-0.55452,"marketCap":20102446},{"date":"2026-05-08","current":-1.779415,"twenty":-0.838489,"median":-0.62112,"eighty":-0.555851,"marketCap":14769144},{"date":"2026-05-15","current":-2.224901,"twenty":-0.870913,"median":-0.625846,"eighty":-0.556353,"marketCap":18466677},{"date":"2026-05-22","current":-2.062736,"twenty":-0.91452,"median":-0.627168,"eighty":-0.558257,"marketCap":17120709},{"date":"2026-05-29","current":-2.296253,"twenty":-0.955372,"median":-0.628812,"eighty":-0.55988,"marketCap":19058903},{"date":"2026-06-05","current":-2.043276,"twenty":-1.009476,"median":-0.634045,"eighty":-0.560702,"marketCap":16959193},{"date":"2026-06-12","current":-2.118586,"twenty":-1.18766,"median":-0.639458,"eighty":-0.562877,"marketCap":17584261},{"date":"2026-06-18","current":-2.043276,"twenty":-1.814564,"median":-0.642142,"eighty":-0.565545,"marketCap":16959193},{"date":"2026-06-26","current":-2.30274,"twenty":-1.957423,"median":-0.652667,"eighty":-0.566624,"marketCap":19112742},{"date":"2026-07-02","current":-2.497338,"twenty":-2.043276,"median":-0.658096,"eighty":-0.570197,"marketCap":20727903},{"date":"2026-07-10","current":-2.678962,"twenty":-2.05625,"median":-0.697542,"eighty":-0.572325,"marketCap":22235387},{"date":"2026-07-17","current":-2.536257,"twenty":-2.075709,"median":-0.73457,"eighty":-0.573176,"marketCap":21050935},{"date":"2026-07-24","current":-2.464905,"twenty":-2.085416,"median":-0.750891,"eighty":-0.576613,"marketCap":20458709},{"date":"2026-07-31","current":-2.180403,"twenty":-2.102953,"median":-0.781666,"eighty":-0.580006,"marketCap":18097343},{"date":"2026-08-07","current":-2.166522,"twenty":-2.154845,"median":-0.801508,"eighty":-0.582361,"marketCap":17982129},{"date":"2026-08-14","current":-2.335173,"twenty":-2.160035,"median":-0.815737,"eighty":-0.587749,"marketCap":19381935},{"date":"2026-08-21","current":-2.185981,"twenty":-2.167171,"median":-0.833563,"eighty":-0.589629,"marketCap":18143645},{"date":"2026-08-28","current":-2.380043,"twenty":-2.188576,"median":-0.837687,"eighty":-0.590513,"marketCap":19754357},{"date":"2026-09-04","current":-2.331329,"twenty":-2.227496,"median":-0.85736,"eighty":-0.590877,"marketCap":19350028},{"date":"2026-09-11","current":-2.352206,"twenty":-2.24955,"median":-0.871696,"eighty":-0.593951,"marketCap":19523312}],"updateTime":1789313906121},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCEL\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1188974254","title":"NewcelX任命世界知名糖尿病治療先驅Camillo Ricordi博士加入科學顧問委員會","url":"https://stock-news.laohu8.com/highlight/detail?id=1188974254","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188974254?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 21:22","pubTimestamp":1783516979,"startTime":"0","endTime":"0","summary":"NewcelX Ltd.宣布，已正式聘请国际知名糖尿病治疗领域先驱Camillo Ricordi博士加入其科学顾问委员会。这一重要人事任命标志着公司在糖尿病创新疗法研发方面迈出了关键一步。\nRicordi博士在胰岛移植和免疫耐受研究领域享有崇高声誉，其开创性工作为糖尿病治疗带来了革命性前景。他的加入预计将为NewcelX的科学战略方向提供权威指导，并加速相关治疗方案的临床转化进程。\n公司表示，此次引进顶尖学术人才，旨在强化研发管线的科学基础，并进一步提升在细胞治疗领域的核心竞争力。业界观察人士认为，该举措可能对NewcelX未来在代谢疾病治疗市场的布局产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121312334","title":"Newcelx宣佈FDA臨床前會議成功，為Ncel-101啓動1型糖尿病臨床試驗鋪平道路","url":"https://stock-news.laohu8.com/highlight/detail?id=1121312334","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121312334?lang=zh_tw&edition=fundamental","pubTime":"2026-07-01 21:35","pubTimestamp":1782912913,"startTime":"0","endTime":"0","summary":"Newcelx宣布，其与FDA就Ncel-101项目举行的临床前会议取得圆满成功，为推进该疗法针对1型糖尿病的临床试验明确了清晰的路径。此次会议成果标志着公司在该创新疗法的开发进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191094520","title":"NewcelX公布2025財年業績 攜手Eledon製藥加速推進2026年1型糖尿病療法研發進程","url":"https://stock-news.laohu8.com/highlight/detail?id=1191094520","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191094520?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 20:17","pubTimestamp":1777551441,"startTime":"0","endTime":"0","summary":"生物技术公司NewcelX Ltd. 近日正式披露2025年度财务报告，同时向投资者同步了与Eledon Pharmaceuticals, Inc. 合作研发1型糖尿病治疗方案的重大进展。据悉，双方将于2026年全面加速该创新疗法的临床开发进程，标志着代谢疾病治疗领域或将迎来突破性技术迭代。若临床进展符合预期，该联合疗法或将成为全球首款通过免疫调控机制逆转1型糖尿病病理进程的生物制剂，潜在市场空间可观。随着研发进程的加速，NewcelX与Eledon制药的技术协同效应将持续释放价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174997049","title":"Newcelx更新企業演示文稿，重點展示與Eledon製藥戰略合作後的1型糖尿病旗艦項目，瑞士生物技術會議前揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=1174997049","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174997049?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 19:37","pubTimestamp":1776685035,"startTime":"0","endTime":"0","summary":"Newcelx已更新其企业演示文稿，着重强调与Eledon制药达成战略合作后的1型糖尿病旗舰项目。这一更新恰逢瑞士生物技术会议召开前夕，凸显了公司对该项目的重视与推进决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NCEL\",params:#limit:6,delay:false,,,undefined,":[]}}